Published in Br J Clin Pract Suppl on April 01, 1986
Side effects with amiodarone therapy. Postgrad Med J (1994) 0.84
Frequency of risk factors for ischaemic heart-disease in a healthy British population. With particular reference to serum-lipoprotein levels. Lancet (1974) 8.19
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (2000) 4.54
Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation (2003) 4.48
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
Torsade De Pointes, an atypical ventricular tachycardia. Br Heart J (1976) 4.22
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol (1997) 3.64
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation (2002) 3.22
Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J (1972) 3.05
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet (2001) 3.02
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol (2000) 2.89
Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol (1990) 2.67
Cardiac fatigue following prolonged endurance exercise of differing distances. Med Sci Sports Exerc (2000) 2.47
Community study of the causes of "natural" sudden death. BMJ (1988) 2.44
Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol (1983) 2.34
Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med (1999) 2.32
Expression of inducible nitric oxide synthase in human heart failure. Circulation (1996) 2.26
Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J (1999) 2.24
Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart (2004) 2.22
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J (1985) 2.22
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16
Echocardiographic measurement of the normal adult right ventricle. Br Heart J (1986) 2.16
Verapamil in the treatment of paroxysmal supraventricular tachycardia. Postgrad Med J (1974) 2.08
Effect of nifedipine on atrioventricular conduction as compared with verapamil. Intracardiac electrophysiological study. Br Heart J (1979) 2.06
Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol (1998) 2.03
Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart (2007) 1.97
Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J (1981) 1.91
Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol (1990) 1.91
High-density substrate mapping in Brugada syndrome: combined role of conduction and repolarization heterogeneities in arrhythmogenesis. Circulation (2009) 1.83
Life-threatening arrhythmias and intravenous cimetidine. Br Med J (1979) 1.81
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation (1999) 1.76
Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol (2001) 1.74
Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation (1990) 1.73
M mode echocardiography in hypertrophic cardiomyopathy: diagnostic criteria and prediction of obstruction. Am J Cardiol (1980) 1.72
Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol (1999) 1.71
Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest (1994) 1.69
Paracetamol and the kidney. Br Med J (1967) 1.68
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart (2000) 1.66
Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol (1992) 1.66
Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Br Heart J (1980) 1.64
Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation (2001) 1.64
QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J (1996) 1.63
Clinical significance of giant negative T waves in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.60
Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. Cardiology (2008) 1.57
Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol (1992) 1.57
Acute and chronic haemodynamic and electrophysiological effects of nifedipine in patients receiving atenolol. Br Heart J (1983) 1.52
Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation (1997) 1.48
Catheter ablation for successful management of left posterior fascicular tachycardia: an approach guided by recording of fascicular potentials. Heart (1996) 1.47
Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J (1981) 1.46
Q waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. J Am Coll Cardiol (1990) 1.45
Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart (1999) 1.45
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation (1999) 1.44
Ventricular tachycardia of left bundle branch block configuration in patients with isolated right ventricular dilatation. Clinical and electrophysiological features. Br Heart J (1984) 1.42
Clinical anatomy of the atrioventricular junctions. J Am Coll Cardiol (1994) 1.41
Reflex responses of venous capacitance vessels in patients with hypertrophic cardiomyopathy. Clin Sci (Lond) (1998) 1.41
Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J (1988) 1.41
Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br Heart J (1989) 1.40
Side effects and possible contraindications of amiodarone use. Am Heart J (1983) 1.40
Human chagasic disease is not associated with an antiheart humoral response. Am J Cardiol (1997) 1.40
Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J (1996) 1.39
Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation (1992) 1.38
Successful radiofrequency ablation of accessory pathways with the first energy delivery: the anatomic and electrical characteristics. Eur Heart J (1996) 1.38
Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation (1992) 1.38
Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest (1995) 1.37
Familial dilated cardiomyopathy in the United Kingdom. Br Heart J (1995) 1.37
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J (1999) 1.36
Rapid and safe termination of supraventricular tachycardia in children by adenosine. Lancet (1987) 1.35
Amiodarone therapy during pregnancy. Am J Cardiol (1983) 1.35
Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol (1997) 1.32
Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation (1998) 1.31
Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol (1980) 1.30
Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child (1984) 1.29
Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J (1999) 1.29
Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance. Biophys J (2009) 1.28
Treatment of refractory supraventricular arrhythmias with flecainide acetate. Arch Dis Child (1987) 1.28
Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol (2000) 1.28
Arrhythmia as a cause of sudden death in hypertrophic cardiomyopathy. Lancet (1976) 1.27
Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol (2000) 1.27
Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol (1984) 1.26
A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation (2000) 1.26
Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol (1995) 1.26
The relationship between posture, blood pressure and electrophysiological properties in patients with paroxysmal supraventricular tachycardia. Arch Mal Coeur Vaiss (1978) 1.25